Clinical Signals and Strategic Shifts: Insights That Shape Oncology Drug Development

Oncology drug development is advancing rapidly, driven by innovation in personalized medicine, precision strategies and immuno-oncology.

The current landscape is marked by a surge in clinical trials exploring novel mechanisms of action, biomarker-guided approaches and combination therapies, each designed to overcome resistance and improve efficacy in increasingly targeted patient populations.

What treatment modalities are capturing oncologists’ attention, and why now? As immuno-oncology continues to evolve, which emerging therapies are poised to reshape the standard of care?

Is the next wave of antibody-drug conjugate (ADC) innovation — including integration with bispecific and tri-specific platforms — delivering on its promise to transform precision oncology, or are we still chasing potential? And as new clinical signals emerge, how are they influencing strategies around trial design, commercialization and pipeline prioritization?

These questions and more will be answered through a survey of HCPs attending the European Society for Medical Oncology (ESMO) annual meeting, one of the premier events in the oncology community, bringing together thousands of oncologists, researchers and healthcare professionals from around the world to share the latest scientific developments, research findings and clinical advancements in cancer treatment.

Join this webinar to gain a deeper understanding of emerging trends and innovations driving the future of cancer care. This includes advances in immuno-oncology, which are delivering longer-lasting responses, and ADCs, which are redefining precision treatment through targeted delivery of potent therapies.

Register to learn which treatment modalities and research are not only capturing the attention of oncologists and reshaping clinical practice but also opening new pathways for market differentiation and commercial success.

Speakers

Dr. Jozsef Palatka, MD, Vice President, Medical Management, Syneos Health

Dr. Jozsef Palatka is a seasoned oncology drug developer with over 25 years of experience leading clinical development across CRO and pharmaceutical organizations. Dr. Palatka has overseen global programs involving PI3K/AKT/mTOR inhibitors, antibody-drug conjugates (ADCs) and bispecific antibodies. He brings deep expertise in adaptive trial designs, master protocols and biomarker-driven strategies that accelerate oncology development while maintaining regulatory rigor.

Message Presenter

Dr. Rob Berg, MD, PhD, Vice President, Medical Management, Syneos Health

With more than 24 years in oncology drug development across biotech, pharma and CRO settings, Dr. Rob Berg brings a dual background as a certified physician and molecular biologist. He has served as Global Medical Lead on multiple pivotal studies supporting approved oncology therapies and brings deep expertise in early phase clinical strategy, targeted therapies and innovative trial designs that accelerate development while ensuring regulatory compliance.

Message Presenter

Marek Rombel, Managing Director, Commercial Advisory, Syneos Health

Marek Rombel is a Managing Director in Syneos Health’s Commercial Advisory Group. He has 25+ years of industry experience, has launched 15 brands and worked on 20 early-stage assets in multiple diseases across the globe, the EU and emerging markets. As a global franchise head, commercial excellence leader and organizational effectiveness professional he has transformed and streamlined many core commercial processes, working across multiple functions including marketing, sales, NPP, L&D, medical and commercial excellence.

Message Presenter